X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
iDose® TR (travoprost intracameral implant) is a prostaglandin analog. It s indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension.
Lead Product(s): Travoprost
Therapeutic Area: Ophthalmology Product Name: iDose TR
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2024
Details:
iDose® TR (Travoprost Intracameral Implant) is a prostaglandin analog. It s indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension
Lead Product(s): Travoprost
Therapeutic Area: Ophthalmology Product Name: iDose TR
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Celanese
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 29, 2024
Details:
iDose TR (travoprost intracameral implant) is a prostaglandin analog indicated for the reduction of intraocular pressure (IOP) in patients with ocular hypertension (OHT) or open-angle glaucoma (OAG).
Lead Product(s): Travoprost
Therapeutic Area: Ophthalmology Product Name: iDose TR
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2023
Details:
Under the agreement, Glaukos gains exclusive worldwide rights to develop and commercialize Stuart's proprietary ST-113, a synthesized collagen mimetic peptide, drug candidate for neuroprotection in glaucoma.
Lead Product(s): ST-113
Therapeutic Area: Ophthalmology Product Name: ST-113
Highest Development Status: IND EnablingProduct Type: Peptide
Recipient: Stuart Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 18, 2023
Details:
iDose TR contains a novel formulation of travoprost, a prostaglandin analog used to lower intraocular pressure. Once all the travoprost is released, the iDose TR is then removed and replaced with a new iDose TR, thus offers a dropless alternative to daily eye drop treatment.
Lead Product(s): Travoprost
Therapeutic Area: Ophthalmology Product Name: iDose TR
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2023
Details:
Glaukos will supply its VitalDose® Drug Delivery Platform for use as a component in Glaukos’ iDose® TR (travoprost), a micro-invasive intraocular implant designed to lower intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension.
Lead Product(s): Travoprost
Therapeutic Area: Ophthalmology Product Name: iDose TR
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Celanese
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 05, 2023
Details:
iDose TR contains a novel formulation of travoprost, a prostaglandin analog used to lower intraocular pressure. Once all the travoprost is released, the iDose TR is then removed and replaced with a new iDose TR, thus offers a dropless alternative to daily eye drop treatment.
Lead Product(s): Travoprost
Therapeutic Area: Ophthalmology Product Name: iDose TR
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2023
Details:
iDose TR contains a novel formulation of travoprost, a prostaglandin analog used to lower intraocular pressure. Once all the travoprost is released, the iDose TR is then removed and replaced with a new iDose TR, thus offers a dropless alternative to daily eye drop treatment.
Lead Product(s): Travoprost
Therapeutic Area: Ophthalmology Product Name: iDose TR
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2023
Details:
93% of Slow-Release iDose TR (travoprost) Subjects Remained Well-Controlled on the Same or Fewer IOP-Lowering Topical Medications at 12 Months After a Single Administration of iDose TR, Including 81% Completely Free of IOP-Lowering Medications.
Lead Product(s): Travoprost
Therapeutic Area: Ophthalmology Product Name: iDose TR
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
Under the licensing agreement with Glaukos Corporation that grants Glaukos an exclusive global license to develop and commercialize IVMED-80 (copper sulfate), a pharmacologic treatment for keratoconus.
Lead Product(s): Copper Sulphate Pentahydrate
Therapeutic Area: Ophthalmology Product Name: IVMED-80
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: iVeena
Deal Size: Undisclosed Upfront Cash: $10.0 million
Deal Type: Licensing Agreement August 24, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
